Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report

被引：0
|
作者：
Barot, Hasti [1 ]
Evans, Joanne [1 ]
Mohammed, Waleed [1 ]
Power, Danielle [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, London, England
来源：
LUNG CANCER | 2022年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [21] Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
    Inno, Alessandro
    Marchetti, Fabiana
    Valerio, Matteo
    Levra, Niccolo Giaj
    Alongi, Filippo
    Foti, Giovanni
    Gori, Stefania
    DRUG TARGET INSIGHTS, 2023, 17 : 90 - 91
  • [22] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [23] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (vol 389, pg 2125, 2023)
    Fakih, Marwan G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (07): : 728 - 728
  • [24] Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRAS G12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report
    Stratton, Natalie
    Thompson, Jonathan
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
  • [25] KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
    Mohn, Deanna
    Saiki, Anne Y.
    Achanta, Pragathi
    Stapper, Andres Plata
    Lipford, J. Russell
    Verma, Rati
    CANCER RESEARCH, 2023, 83 (07)
  • [26] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
    Clarke, J. M.
    Felip, E.
    Li, B. T.
    Ruffinelli, J. C.
    Garrido, P.
    Zugazagoitia, J.
    Goldberg, S. B.
    Ramalingam, S. S.
    Victoria, I.
    Puri, S.
    Gandara, D. R.
    Varrieur, T.
    Edmonds, S.
    Palmer, K.
    Snyder, W.
    Govindan, R.
    Rybkin, I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
  • [27] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
    Marinelli, D.
    Pisegna, S.
    Giammaruco, M.
    Chesi, P.
    Mammone, G.
    Ceddia, S.
    Gazzaniga, P.
    Cortesi, E.
    Gelibter, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
  • [28] Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    TARGETED ONCOLOGY, 2024, 19 (03) : 297 - 301
  • [29] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
  • [30] Anti-KRAS G12C and Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C-Mutated Colorectal Cancer: A Case Report
    Morris, Linda
    Pappas, Leontios
    Pandey, Aditya
    Singh, Harshabad
    Klempner, Samuel
    Caughey, Bennett
    JCO PRECISION ONCOLOGY, 2024, 8
12345